作为伊马替尼类似物,是一种共价不可逆激酶抑制剂,对ABL1 wt、KIT wt、PDGFRR wt的IC50分别为6.95 μM、2.45 μM、1.39 μM,用于相关激酶靶点的抑制研究及潜在药物开发。
医药
合成路线 1(1. 合成:404844-11-7)
- 步骤: 1. 将6-甲基-N1-(4-(吡啶-3-基)嘧啶-2-基)苯-1,3-二胺(10.0g,36.0mmol)和三乙胺(10.0ml,72.2mmol)溶于四氢呋喃(100mL)中,冷却至0℃并保持10分钟;2. 逐滴加入4-(氯甲基)苯甲酰氯(7.8g,41.4mmol)的四氢呋喃(50mL)溶液,0℃搅拌4小时后,滴加水(500ml),抽滤收集沉淀,用水洗涤并干燥,得到4-(氯甲基)-N-(4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)氨基)苯基)苯甲酰胺(15.1g,收率97.4%);3. 将该物质(4g,93mmol)和叔丁基哌嗪甲酸酯(8.8g,465mmol)溶解在N-甲基-2-吡咯烷酮(20mL)中,微波120℃反应1小时,冷却后加二氯甲烷,用1M盐酸萃取,酸性水相中和后二氯甲烷萃取,合并有机层干燥浓缩,柱色谱纯化得到4-(4-((4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)叔丁基)氨基)苯基)氨基甲酰基)苄基)哌嗪-1-羧酸酯(72%收率);4. 将该物质(580mg,1mmol)溶于盐酸的乙酸乙酯溶液(5mL,4M),室温搅拌2小时后减压浓缩,得到N-(4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)氨基)苯基)-4-(哌嗪-1-基甲基)苯甲酰胺的盐酸盐;5. (5Z,8Z,11Z,14Z,17Z)-二十碳-5,8,11,14,17-五烯酸(EPA,0.27g,0.92mmol)与HATU(0.47g,1.24mmol)、三乙胺(0.25g,2.49mmol)和上述盐酸盐(0.4g,0.83mmol)在15mL二氯甲烷中反应,室温搅拌16小时,稀释后用氯化铵水溶液和盐水洗涤,干燥浓缩,硅胶色谱纯化得到目标产物(产率62%)。
- 收率: 97.4%(第一步);72%(第二步);62%(最终产物)
- 条件: 0℃;微波120℃;室温;二氯甲烷、N-甲基-2-吡咯烷酮等溶剂
- 参考文献: [1] ChemMedChem, 2017, vol. 12, # 7, p. 487 - 501;[2] Patent: WO2014/204856, 2014, A1. Location in patent: Paragraph 0310-0311;[3] Patent: WO2006/71130, 2006, A2. Location in patent: Page/Page column 25-27;[4] Tetrahedron Letters, 2012, vol. 53, # 49, p. 6657 - 6661;[5] Patent: US9095622, 2015, B2. Location in patent: Page/Page column 33;[6] Organic Letters, 2012, vol. 14, # 15, p. 3920 - 3923;[7] Organic Process Research and Development, 2008, vol. 12, # 3, p. 490 - 495;[8] Patent: CN104844566, 2018, B. Location in patent: Paragraph 0124-0126;[9] Russian Journal of Organic Chemistry, 2015, vol. 51, # 1, p. 101 - 109;[10] Zh. Org. Khim., 2015, vol. 51, # 1, p. 104 - 111,8;[11] European Journal of Medicinal Chemistry, 2018, vol. 150, p. 366 - 384;[12] Patent: EP3133069, 2017, A1. Location in patent: Paragraph 0039;[13] Patent: WO2004/108699, 2004, A1. Location in patent: Page 20-43;[14] Angewandte Chemie, International Edition, 2015, vol. 54, # 1, p. 179 - 183;[15] Angewandte Chemie, 2015, vol. 127, # 1, p. 181 - 185,5;[16] Journal of Medicinal Chemistry, 2005, vol. 48, # 1, p. 249 - 255;[17] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 15, p. 4248 - 4253;[18] Patent: WO2004/99186, 2004, A1. Location in patent: Page 9; 14-15;[19] Patent: WO2004/99187, 2004, A1. Location in patent: Page 8-9; 14